Bausch & Lomb optimistic on FDA approval for laser
This article was originally published in Clinica
The share price of eye healthcare company Bausch & Lomb rose by nearly 8% last week on the announcement that the company was "highly confident" that the US FDA would waive a panel review of its pre-market approval application by the ophthalmic devices panel for its laser for LASIK refractive surgery procedures.
You may also be interested in...
The physician who led the first first-in-human robotic-assisted neurovascular intervention with Corindus’ CorPath GRX system believes the technology could revolutionize neurovascular intervention by allowing a centralized interventional team to remotely treat patients.
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.